Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06786533 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
A Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), sponsored by Hemogenyx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06786533: Recruiting Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), sponsored by Hemogenyx Pharmaceuticals.
NCT06786533 is a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) that is actively recruiting participants, run by Hemogenyx Pharmaceuticals. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06786533, a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), is actively recruiting participants, sponsored by Hemogenyx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediatric subjects will be enrolled. Evaluable subjects are defined as those who have received an infusion of HG-CT-1. Primary clinical objectives: i. Determine the safety of HG-CT-1 based on the proportion of subjects infused with HG-CT-1 who experience a dose limiting toxicity (DLT). Secondary clinical objectives: i. Estimate the efficacy of HG-CT-1 according to standard clinical response criteria for AML. ii. Estimate overall survival of evaluable subjects. iii. Estimate progression-free survival of evaluable subjects. iv. Estimate duration of response in evaluable subjects who achieve a response. Secondary scientific objectives: i. Describe the persistence and trafficking of HG-CT-1. ii. Describe HG-CT-1 bioactivity and its predictors.
Primary Outcome
Occurrence of dose-limiting toxicities related to HG-CT-1. First-in-human study with unknown safety of infusion of HG-CT-1.
Conditions Studied
Interventions
- DRUG Anti-FLT3 CAR-T cells
Study Locations (1)
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT06786533 shows while recruiting
NCT06786533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) appearing as the primary indexed condition, and to 1 intervention - of which Anti-FLT3 CAR-T cells is the first listed.
NCT06786533 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06786533 about?
NCT06786533 is a clinical study titled "Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML". This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediatric subjects will be enrolled. Evaluable subjects are defined as those who have received an infusion...
What is the current status of trial NCT06786533?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-01-23. Estimated completion is 2027-01.
What conditions does trial NCT06786533 study?
This clinical trial studies the following conditions: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
What interventions are being tested in trial NCT06786533?
The interventions under investigation include: Anti-FLT3 CAR-T cells (DRUG).
Who is sponsoring clinical trial NCT06786533?
This trial is sponsored by Hemogenyx Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06786533 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06786533's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI